KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Equity (2020 - 2025)

Recursion Pharmaceuticals' Return on Equity history spans 6 years, with the latest figure at 0.59% for Q4 2025.

  • For Q4 2025, Return on Equity changed 0.0% year-over-year to 0.59%; the TTM value through Dec 2025 reached 0.59%, changed 0.0%, while the annual FY2025 figure was 0.6%, 2.0% up from the prior year.
  • Return on Equity reached 0.59% in Q4 2025 per RXRX's latest filing, up from 0.73% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.44% in Q1 2021 to a low of 0.82% in Q1 2024.
  • Average Return on Equity over 5 years is 0.54%, with a median of 0.59% recorded in 2023.
  • Peak YoY movement for Return on Equity: plummeted -84bps in 2022, then increased 24bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.32% in 2021, then tumbled by -76bps to 0.56% in 2022, then fell by -29bps to 0.73% in 2023, then grew by 18bps to 0.59% in 2024, then rose by 0bps to 0.59% in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Return on Equity are 0.59% (Q4 2025), 0.73% (Q3 2025), and 0.7% (Q2 2025).